

Pubblicazioni su riviste internazionali

1. Emergence of KPC-producing *Klebsiella pneumoniae* in Italy.

Fontana C, Favaro M, Sarmati L, Natoli S, Altieri A, Bossa MC, Minelli S, Leonardis F, Favalli C.

BMC Res Notes. 2010 Feb 23;3:40.

2. Comparison of the eSwab collection and transportation system to an amies gel transystem for Gram stain of clinical specimens.

Fontana C, Favaro M, Limongi D, Pivonkova J, Favalli C.

BMC Res Notes. 2009 Dec 10;2:244.

3. A novel culturing system for fluid samples.

Fontana C, Favaro M, Minelli S, Bossa MC, Altieri A, Favalli C.

Med Sci Monit. 2009 Feb;15(2):BR55-60.

4. Proteomic investigation in A549 lung cell line stably infected by HPV16E6/E7 oncogenes.

Ciotti M, Marzano V, Giuliani L, Nuccetelli M, D'Aguanno S, Azzimonti B, Bernardini S, Perno CF, Urbani A, Favalli C, Federici G.

Respiration. 2009;77(4):427-39. Epub 2008 Nov 20.

5. Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways.

Paba P, Bonifacio D, Di Bonito L, Ombres D, Favalli C, Syrjänen K, Ciotti M.

Intervirology. 2008;51(4):230-4. Epub 2008 Sep 24.

6. Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens.

Giorgi C, Di Bonito P, Grasso F, Mochi S, Accardi L, Donà MG, Branca M, Costa S, Mariani L, Agarossi A, Ciotti M, Syrjänen K; HPV-PathogenISS group.

Infect Agent Cancer. 2008 Jun 26;3:9.

7. Acinetobacter baumannii in intensive care unit: a novel system to study clonal relationship among the isolates.

Fontana C, Favaro M, Minelli S, Bossa MC, Testore GP, Leonardis F, Natoli S, Favalli C.

BMC Infect Dis. 2008 Jun 8;8:79.

8. Detection of oncogenic DNA viruses in colorectal cancer.

Giuliani L, Ronci C, Bonifacio D, Di Bonito L, Favalli C, Perno CF, Syrjänen K, Ciotti M.

Anticancer Res. 2008 Mar-Apr;28(2B):1405-10.

9. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.

Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Int J Gynecol Pathol. 2008 Apr;27(2):265-73.

10. Human papillomavirus infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature.

Giuliani L, Favalli C, Syrjanen K, Ciotti M.

Anticancer Res. 2007 Jul-Aug;27(4C):2697-704. Review.

11. BK virus DNA detection by real-time polymerase chain reaction in clinical specimens.

Marchetti S, Graffeo R, Siddu A, Santangelo R, Ciotti M, Picardi A, Favalli C, Fadda G, Cattani P.

New Microbiol. 2007 Apr;30(2):119-26.

12. Thymosin alpha 1: from bench to bedside.

Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, Pierimarchi P, Serafino A, Mastino A, Bistoni F, Romani L, Rasi G.

Ann N Y Acad Sci. 2007 Sep;1112:225-34. Epub 2007 Jun 28.

13. The combined use of VIGI@ct (bioMérieux) and fluorescent amplified length fragment polymorphisms in the investigation of potential outbreaks.

Fontana C, Favaro M, Pistoia ES, Minelli S, Bossa MC, Altieri A, Testore GP, Leonardis F, Natoli S, Favalli C.

J Hosp Infect. 2007 Jul;66(3):262-8. Epub 2007 Jun 1.

14. Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma.

Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D'Antonio D, Syrjanen K, Favalli C, Ciotti M.

Lung Cancer. 2007 Sep;57(3):273-81. Epub 2007 Apr 2.

15. Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy.

Grelli S, Balestrieri E, Matteucci C, Minutolo A, D'Ettorre G, Lauria F, Montella F, Vullo V, Vella S, Favalli C, Mastino A, Macchi B.

Ann N Y Acad Sci. 2006 Dec;1090:130-7.

16. Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy.

Balestrieri E, Grelli S, Matteucci C, Minutolo A, d'Ettorre G, Di Sora F, Montella F, Vullo V, Vella S, Favalli C, Macchi B, Mastino A.

J Med Virol. 2007 Feb;79(2):111-7.

17. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer.

Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):223-31. Epub 2006 Nov 13.

18. Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping.

Giuliani L, Coletti A, Syrjänen K, Favalli C, Ciotti M.

Anticancer Res. 2006 Sep-Oct;26(5B):3939-41.

19. The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections.

Ciotti M, Coletti A, Giuliani L, Cappiello G, Syrjanen K, Favalli C.

Anticancer Res. 2006 Sep-Oct;26(5B):3745-8.

20. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen S, Favalli C, Syrjänen K.

Diagn Cytopathol. 2006 Nov;34(11):739-48.

21. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen SM, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Int J Gynecol Pathol. 2006 Oct;25(4):383-92

22. Entire genome of a strain of human immunodeficiency virus type 1 with a deletion of nef that was recovered 20 years after primary infection: large pool of proviruses with deletions of env.

Calugi G, Montella F, Favalli C, Benedetto A.

J Virol. 2006 Dec;80(23):11892-6. Epub 2006 Sep 20.

23. Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen S, Favalli C, Syrjänen K; HPV-Pathogen ISS Study Group.

Diagn Cytopathol. 2006 Aug;34(8):555-63.

24. Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Eur J Gynaecol Oncol. 2006;27(3):215-23.

25. Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer.

Ciotti M, Giuliani L, Ambrogi V, Ronci C, Benedetto A, Mineo TC, Syrjänen K, Favalli C.

Oncol Rep. 2006 Jul;16(1):183-9.

26. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.

Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Anticancer Res. 2006 Mar-Apr;26(2B):1543-56.

27. Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Favalli C, Syrjänen K; HPV-Pathogen Istituto Superiore di Sanità Study Group.

J Clin Pathol. 2006 Oct;59(10):1044-51. Epub 2006 Mar 14.

28. Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Acta Cytol. 2006 Jan-Feb;50(1):6-15.

29. Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Benedetto A, Paba P, Costa S, Bonifacio D, Di Bonito P, Accardi L, Favalli C, Syrjänen K; HPV-Pathogen ISS Study Group.

J Clin Pathol. 2006 Jan;59(1):40-7.

30. Single or multiple HPV types in cervical cancer and associated metastases.

Ciotti M, Paba P, Bonifacio D, Di Bonito L, Benedetto A, Favalli C.

Oncol Rep. 2006 Jan;15(1):143-8.

31. Performance of strand displacement amplification assay in the detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Fontana C, Favaro M, Cicchetti O, Minelli S, Pistoia ES, Favalli C.

Jpn J Infect Dis. 2005 Oct;58(5):283-8.

32. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction.

Mango R, Biocca S, del Vecchio F, Clementi F, Sangiuolo F, Amati F, Filareto A, Grelli S, Spitalieri P, Filesì I, Favalli C, Lauro R, Mehta JL, Romeo F, Novelli G.

Circ Res. 2005 Jul 22;97(2):152-8. Epub 2005 Jun 23.

33. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer.

Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjänen S, Bonifacio D, Accardi L, Zanconati F, Syrjänen K; HPV-Pathogen ISS Study Group.

Am J Clin Pathol. 2005 Jul;124(1):113-21.

34. Use of the MicroSeq 500 16S rRNA gene-based sequencing for identification of bacterial isolates that commercial automated systems failed to identify correctly.

Fontana C, Favaro M, Pelliccioni M, Pistoia ES, Favalli C.

J Clin Microbiol. 2005 Feb;43(2):615-9.

35. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study.

Branca M, Costa S, Mariani L, Sesti F, Agarossi A, di Carlo A, Galati M, Benedetto A, Ciotti M, Giorgi C, Criscuolo A, Valieri M, Favalli C, Paba P, Santini D, Piccione E, Alderisio M, De Nuzzo M, di Bonito L, Syrjänen K.

Eur J Gynaecol Oncol. 2004;25(6):689-98.

36. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer.

Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M, Syrjänen K; HPV-Pathogen ISS Study Group.

Am J Clin Pathol. 2004 Dec;122(6):902-11.

37. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.

Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjänen K, Favalli C.

Eur J Gynaecol Oncol. 2004;25(5):577-84.

38. p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome.

Branca M, Ciotti M, Santini D, Di Bonito L, Giorgi C, Benedetto A, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M, Syrjänen K.

Int J Gynecol Pathol. 2004 Oct;23(4):354-65.

39. Polyoma virus BK and renal dysfunction in a transplanted population.

Splendiani G, Cipriani S, Condò S, Paba P, Ciotti M, Favalli C, Vega A, Dominijanni S, Casciani CU.

Transplant Proc. 2004 Apr;36(3):713-5.

40. CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis.

Grelli S, D'Ettore G, Lauria F, Montella F, Di Traglia L, D'Agostini C, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A.

Ann N Y Acad Sci. 2003 Dec;1010:560-4. Review

41. Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients.

Grelli S, d'Ettore G, Lauria F, Montella F, Di Traglia L, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A.

J Antimicrob Chemother. 2004 Mar;53(3):494-500. Epub 2004 Feb 12.

42. Detection of clarithromycin-resistant Helicobacter pylori in stool samples.

Fontana C, Favaro M, Pietroiusti A, Pistoia ES, Galante A, Favalli C.

J Clin Microbiol. 2003 Aug;41(8):3636-40.

43. Umbilical cord blood: the role of apoptosis in the control of CD34+ cell counts.

Mastino A, Favalli C, Camilli AR, Malerba C, Grelli S, Calugi A.

Placenta. 2003 Jan;24(1):113-5.

44. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates.

Fontana C, Favaro M, Minelli S, Criscuolo AA, Pietroiusti A, Galante A, Favalli C.

Antimicrob Agents Chemother. 2002 Dec;46(12):3765-9.

45. C-reactive protein is increased in patients with degenerative aortic valvular stenosis.

Galante A, Pietroiusti A, Vellini M, Piccolo P, Possati G, De Bonis M, Grillo RL, Fontana C, Favalli C.

J Am Coll Cardiol. 2001 Oct;38(4):1078-82.

46. Early and multiple Ac transpositions in rice suitable for efficient insertional mutagenesis.

Greco R, Ouwerkerk PB, Taal AJ, Favalli C, Beguiristain T, Puigdomènech P, Colombo L, Hoge JH, Pereira A.

Plant Mol Biol. 2001 May;46(2):215-27. Erratum in: Plant Mol Biol 2001 Aug;46(6):763-4.

47. Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression.

Grelli S, Di Traglia L, Matteucci C, Lichtner M, Vullo V, Di Sora F, Lauria F, Montella F, Favalli C, Vella S, Macchi B, Mastino A.

AIDS. 2001 Jun 15;15(9):1178-81.

48. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

Garaci E, Pica F, Rasi G, Favalli C.

Int J Immunopharmacol. 2000 Dec;22(12):1067-76. Review.

49. Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy.

Grelli S, Campagna S, Lichtner M, Ricci G, Vella S, Vullo V, Montella F, Di Fabio S, Favalli C, Mastino A, Macchi B.

AIDS. 2000 May 26;14(8):939-49.

50. Infection with Helicobacter pylori and leukocyte response in patients with myocardial infarction.

Galante A, Pietroiusti A, Carta S, Franceschelli L, Piccolo P, Mastino A, Fontana C, Grelli S, Bergamaschi A, Magrini A, Favalli C.

Eur J Clin Microbiol Infect Dis. 2000 Apr;19(4):298-300.

51. Comparison of an enzyme immunoassay versus a rapid latex test for serodiagnosis of Helicobacter pylori infection.

Fontana C, Pietroiusti A, Mastino A, Pistoia ES, Marino D, Magrini A, Galante A, Favalli C.

Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):239-40. No abstract available.

52. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level.

Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, Grelli S, Bucci I, Singer DS, Kohn LD, Monaco F, Garaci E, Favalli C.

Eur J Immunol. 2000 Mar;30(3):778-86.

53. Immunological and endocrinological disturbances in patients after prolonged coma following head injury.

Formisano R, Grelli S, Matteucci C, Santilli V V, Vinicola V V, Scivoletto G, Castellano V V, D'Agostini C, Mastino A, Favalli C.

Eur J Neurol. 1998 Mar;5(2):151-158.

54. Isolation and characterization of a DNA probe for Staphylococcus aureus subspecies aureus biovar.

Fontana C, Favaro M, Frezza D, Favalli C.

FEMS Microbiol Lett. 1999 Mar 1;172(1):47-52.

55. Human Th1 and Th2 T-cell clones are equally susceptible to infection and immortalization by human T-lymphotropic virus type I.

Macchi B, Grelli S, Matteucci C, D'Elis MM, De Carli M, Favalli C, Del Prete G, Mastino A.

J Gen Virol. 1998 Oct;79 (Pt 10):2469-74.

56. Interleukin 4 stimulates infection and temporary growth of human neonatal lymphocytes exposed in vitro to human T-lymphotropic virus type I, but fails to substitute for interleukin 2 in the immortalization of infected cultures.

Mastino A, Grelli S, Favalli C, Matteucci C, De Carli M, Garaci E, Macchi B.

J Gen Virol. 1997 Oct;78 (Pt 10):2565-74.

57. Simple enzymatic method for rapid identification of a Staphylococcus aureus subspecies aureus biovar.

Fontana C, Laratta E, Marino D, Pistoia ES, Favalli C.

Eur J Clin Microbiol Infect Dis. 1997 Sep;16(9):689-92.

58. Leucocyte rheological properties are altered in patients with diffuse atherosclerosis.

Galante A, Pietroiusti A, Magrini A, Carta S, Franceschelli L, Piccolo P, Pistolese GR, Martelli E, Mastino A, Matteucci C, Grelli S, Favalli C.

Thromb Haemost. 1997 Jun;77(6):1073-6.

59. Combination therapy with BRMs in cancer and infectious diseases.

Garaci E, Pica F, Rasi G, Palamara AT, Favalli C.

Mech Ageing Dev. 1997 Jun;96(1-3):103-16. Review.

60. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro.

Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E.

J Gen Virol. 1997 May;78 (Pt 5):1007-16.

61. Antifungal and immunoadjuvant properties of fluconazole in mice immunosuppressed with morphine.

Di Francesco P, Gaziano R, Casalnuovo IA, Palamara AT, Favalli C, Garaci E.

Chemotherapy. 1997 May-Jun;43(3):198-203.

62. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

Rasi G, Mutchnick MG, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F, Favalli C, Garaci E.

J Viral Hepat. 1996 Jul;3(4):191-6.

63. Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway.

Pica F, Franzese O, D'Onofrio C, Bonmassar E, Favalli C, Garaci E.

J Pharmacol Exp Ther. 1996 Jun;277(3):1793-800.

64. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus.

D'Agostini C, Palamara AT, Favalli C, Sivilia M, Febbraro G, Bue C, Garaci E.

Int J Immunopharmacol. 1996 Feb;18(2):95-102.

65. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.

Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P, et al.

Eur J Cancer. 1995 Dec;31A(13-14):2403-5.

66. Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication.

Palamara AT, Perno CF, Ciriolo MR, Dini L, Balestra E, D'Agostini C, Di Francesco P, Favalli C, Rotilio G, Garaci E.

Antiviral Res. 1995 Jun;27(3):237-53.

67. Effect of PGE2 on c-Myc and Bcl-2 production and programmed cell death in human lymphocytes.

Pica F, Franzese O, D'Onofrio C, Paganini L, Favalli C, Bonmassar E, Garaci E.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:457-9.

68. Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.

Venditti A, Scimò MT, del Poeta G, Buccisano F, Stasi R, Mastino A, Grelli S, Favalli C, Garaci E, Papa G.

Leuk Lymphoma. 1995 Jan;16(3-4):335-42.

69. Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

di Francesco P, Gaziano R, Casalnuovo IA, Belogi L, Palamara AT, Favalli C, Garaci E.

Clin Exp Immunol. 1994 Sep;97(3):347-52.

70. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.

D'Antonio D, Piccolomini R, Iacone A, Fioritoni G, Parruti G, Betti S, Quaglietta AM, Accorsi P, Dell'Isola M, Favalli C.

J Antimicrob Chemother. 1994 Apr;33(4):837-44.

71. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.

Garaci E, Rocchi G, Perroni L, D'Agostini C, Soscia F, Grelli S, Mastino A, Favalli C.

Int J Clin Lab Res. 1994;24(1):23-8.

72. Inhibitory effect of morphine on the control of rat fibroblast cell proliferation.

Di Francesco P, Gaziano R, Casalnuovo IA, Palamara AT, Favalli C.

Int J Tissue React. 1994;16(5-6):205-10.

73. Effect of synthetic thymic hormones on the cocaine-induced inhibition of the primary immune response in mice.

Ravagnan G, Falchetti R, Lanzilli G, Di Francesco P, Gaziano R, Favalli C, Garaci E.

Int J Immunopharmacol. 1993 Nov;15(8):879-85.

74. Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV.

Mastino A, Grelli S, Piacentini M, Oliverio S, Favalli C, Perno CF, Garci E.

Cell Immunol. 1993 Nov;152(1):120-30.

75. In vitro phencyclidine-induced inhibition of lymphocyte proliferation: prevention by cell activation.

Di Francesco P, Gaziano R, Pica F, Palamara AT, Innocenti F, Favalli C.

Immunopharmacol Immunotoxicol. 1993 Jan;15(1):69-78.

76. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.

Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C.

J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):7-17.

77. Glutathione inhibits replication and expression of viral proteins in cultured cells infected with Sendai virus.

Garaci E, Palamara AT, Di Francesco P, Favalli C, Ciriolo MR, Rotilio G.

Biochem Biophys Res Commun. 1992 Nov 16;188(3):1090-6.

78. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.

Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, Garaci E.

Int J Cancer. 1992 Feb 1;50(3):493-9.

79. Time-related interference of misoprostol with experimental gastric cancer formation induced by N-methyl-N'-nitro-N-nitrosoguanidine in the rat.

Basso N, Materia A, Silecchia G, Spaziani E, Scucchi L, Di Stefano D, Mingazzini P, Favalli C, Garaci E.

J Cancer Res Clin Oncol. 1992;118(6):441-6.

80. In vivo cocaine administration influences lymphokine production and humoral immune response.

Di Francesco P, Marini S, Pica F, Favalli C, Tubaro E, Garaci E.

Immunol Res. 1992;11(1):74-9.

81. Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration.

Di Francesco P, Pica F, Marini S, Favalli C, Garaci E.

Int J Immunopharmacol. 1992 Jan;14(1):1-9.

82. Induction of apoptosis in thymocytes by prostaglandin E2 in vivo.

Mastino A, Piacentini M, Grelli S, Favalli C, Autuori F, Tentori L, Oliverio S, Garaci E.

Dev Immunol. 1992;2(4):263-71.

83 Susceptibility to influenza A virus infection in mice immunosuppressed with cyclophosphamide.

Mastino A, Grelli S, Premrov MG, Favalli C.

J Chemother. 1991 Jun;3(3):156-61.

84. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.

Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E.

Cell Immunol. 1991 Mar;133(1):196-205.

85. Effect of di-M-PGE2 on T cell differentiation. Flow cytometry study at thymus level.

Mastino A, Grelli S, Favalli C, Garaci E.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:851-4.

86. Inhibition of rat fibroblast cell proliferation at specific cell cycle stages by cocaine.

Di Francesco P, Pica F, Favalli C, Tubaro E, Garaci E.

Cell Biol Int Rep. 1990 Jun;14(6):549-58.

87. Alpha interferon plus thymopentine in treatment of HBV and/or HDV positive patients undergoing liver transplant.

Gaeta A, Mancini C, Bachetoni A, Sallusto F, Lorino G, Marinucci G, Di Giacomo C, Favalli C, Alfani D, Filadoro F.

J Biol Regul Homeost Agents. 1990 Apr-Jun;4(2):51-6.

88. Sequential evaluation of gastric intraluminal prostaglandin E2 release, acid secretion and DNA-flow cytometry in N-methyl-N-nitro-N-nitrosoguanidine gastric carcinogenesis in the rat.

Silecchia G, Materia A, Spaziani E, Mariani P, Scucchi L, Micheli C, Mingazzini P, Mauro F, Favalli C, Basso N.

Cancer Lett. 1990 Jan;49(1):73-80.

89. Mechanism of production of interferon-gamma: role of arachidonic acid metabolites.

Antonelli G, Mastino A, Amicucci P, Turriziani O, Favalli C, Garaci E.

J Biol Regul Homeost Agents. 1990 Jan-Mar;4(1):13-8.

90. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.

Garaci E, Mastino A, Pica F, Favalli C.

Cancer Immunol Immunother. 1990;32(3):154-60.

91. Effect of acute or daily cocaine administration on cellular immune response and virus infection in mice.

Di Francesco P, Pica F, Croce C, Favalli C, Tubaro E, Garaci E.

Nat Immun Cell Growth Regul. 1990;9(6):397-405.

92. Regulation of cell proliferation by inducible-secreted proteins in growth factor-treated EL2 rat fibroblasts.

Di Francesco P, Liboi E, Febbraro G, Favalli C.

J Chemother. 1989 Jul;1(4 Suppl):1174-6.

93. Combined treatment with thymosin alpha 1 and interferon enhances NK activity in immunosuppressed tumor bearing mice.

Pica F, Mastino A, Grelli S, Jezzi T, Favalli C.

J Chemother. 1989 Jul;1(4 Suppl):1167-9.

94. Flow cytometric method for the evaluation of the biological activity of thymic hormones.

Mastino A, Favalli C, Moras ML, Grelli S, Bonmassar E.

J Chemother. 1989 Jul;1(4 Suppl):459-60.

95. Modifications in spleen lymphocyte subsets after cyclophosphamide and 16,16-dimethyl prostaglandin E2 administration in mice.

Mastino A, Favalli C, Jezzi T, Grelli S, Pica F, Garaci E.

J Chemother. 1989 Jul;1(4 Suppl):454-6.

96. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.

Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E.

Int J Immunopharmacol. 1989;11(5):443-50.

97. Role of prostaglandins in the early phases of experimental gastric carcinogenesis in the rat.

Materia A, Silecchia G, Spaziani E, Mariani P, Scucchi L, Mingazzini P, Favalli C, Garaci E, Basso N.

J Cancer Res Clin Oncol. 1989;115(3):253-8.

98. Enhanced immune response and antitumor immunity with combinations of biological response modifiers.

Garaci E, Mastino A, Favalli C.

Bull N Y Acad Med. 1989 Jan;65(1):111-9. Review.

99. Role of prostaglandins in the early stage of gastric carcinogenesis induced by N-methyl-N-nitro-N-nitrosoguanidine (MNNG) in rats.

Silecchia G, Spaziani E, Materia A, Genco A, Scucchi L, Landa García JI, Favalli C, Basso N.

Rev Esp Enferm Apar Dig. 1988 Dec;74(6):635-9. Spanish.

100. Secreted proteins induced by epidermal growth factor and transforming growth factor beta in EL2 rat fibroblasts. Role in the mitogenic response.

Di Francesco P, Favalli C, Liboi E.

Cell Biol Int Rep. 1988 May;12(5):365-72.

101. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus.

Santoro MG, Favalli C, Mastino A, Jaffe BM, Esteban M, Garaci E.

Arch Virol. 1988;99(1-2):89-100.

102. Effect of in vivo administration of prostaglandins and interferon on natural killer activity and on B-16 melanoma growth in mice.

Garaci E, Mastino A, Jezzi T, Riccardi C, Favalli C.

Cell Immunol. 1987 Apr 15;106(1):43-52.

103. Correlation between the effects of prostaglandins and interferon on B-16 melanoma growth and their modulation on natural killer activity.

Favalli C, Mastino A, Grelli S, Garaci E.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:159-62. No abstract available.

104. Modulation of natural killer activity by thymosin alpha 1 and interferon.

Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E.

Cancer Immunol Immunother. 1985;20(3):189-92.

105. Modulation of endogenous prostaglandins by thymosin-alpha 1 in lymphocytes.

Rinaldi-Garaci C, Garaci E, Del Gobbo V, Favalli C, Jezzi T, Goldstein AL.

Cell Immunol. 1983 Aug;80(1):57-65.

106. Is thymosin action mediated by prostaglandin release?

Rinaldi Garaci C, Favalli C, Del Gobbo V, Garaci E, Jaffe BM.

Science. 1983 Jun 10;220(4602):1163-4.

107. Comparison between natural reactivity (NR) against Candida albicans and natural killer (NK) activity against YAC-1 tumour cells.

Bistoni F, Baccarini M, Blasi E, Riccardi C, Favalli C.

Int J Tissue React. 1983;5(1):73-84.

108. The differential effects of PGE on the immune response in normal and immunosuppressed mice.

Favalli C, Leport P, Jaffe BM, Santoro MG, Simmet T, Del Gobbo V, Garaci E.

Cell Immunol. 1982 Sep 15;72(2):351-9.

109. Induction of serum thymic-like activity in adult thymectomized mice by a synthetic analog of PGE₂.

Rinaldi-Garaci C, Del Gobbo V, Favalli C, Garaci E, Bistoni F, Jaffe BM.

Cell Immunol. 1982 Sep 1;72(1):97-101.

110. PGE restores the immune response in chemotherapy-treated, tumor-bearing mice.

Leport P, Favalli C, Santoro MG, Rinaldi C, Jaffe BM.

Life Sci. 1982 Apr 5;30(14):1219-23.

111. A synthetic analog of prostaglandin E₂ is able to induce in vivo theta antigen on spleen cells of adult thymectomized mice.

Garaci E, Rinaldi-Garaci C, del Gobbo V, Favalli C, Santoro MG, Jaffe BM.

Cell Immunol. 1981 Jul 15;62(1):8-14.

112. Influence of PGE on the immune response in melanoma-bearing mice.

Favalli C, Garaci E, Etheredge E, Santoro MG, Jaffe BM.

J Immunol. 1980 Aug;125(2):897-902.

113. The effect of PGA₁ on the immune response in B-16 melanoma-bearing mice.

Favalli C, Garaci E, Santoro MG, Santucci L, Jaffe BM.

Prostaglandins. 1980 Apr;19(4):587-94.